TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

A Media Snippet accompanying this announcement is offered by clicking on this hyperlink.

NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) right this moment introduced a collaboration with actress Christina Applegate to assist increase consciousness of a number of sclerosis (MS) and assist significant conversations for these dwelling with the illness.

Christina Applegate, who has been dwelling with MS for five years, will lead the brand new nationwide disease-awareness initiative designed to elevate the voices of folks dwelling with MS, spotlight the realities, and discover what comes subsequent, on their very own phrases.

The cornerstone of the marketing campaign is www.NextInMS.com, a brand new platform developed to assist folks dwelling with MS. By Subsequent In MS^TM, Christina extends the identical unfiltered honesty she has introduced to her personal expertise into shared conversations with others dwelling with MS. The platform will characteristic unique content material together with Christina’s private views on navigating life with MS, long-term decision-making, participating with the healthcare system, and prioritizing high quality of life whereas dwelling with a persistent situation. It’s anticipated to additionally embody instructional content material from main MS consultants providing present insights on matters of curiosity to the MS neighborhood. Collectively, these efforts are supposed to foster open, knowledgeable dialogue amongst folks dwelling with MS, caregivers, and healthcare professionals.

“MS isn’t one thing you neatly determine and transfer on from — it’s messy, it’s unpredictable and a few days it frankly simply sucks,” mentioned Christina Applegate. “I’ve all the time tried to be sincere about that. Subsequent In MS is about opening up these conversations, increasing our understanding and all the time being ready for what’s subsequent. I’m excited to be partnering with TG Therapeutics, and collectively hopefully we will attain extra members of the MS neighborhood, lower by way of the noise and speak brazenly in regards to the truths of dwelling with MS — the difficult ones and the hopeful ones too.”

Michael S. Weiss, Chairman and Chief Government Officer of TG Therapeutics, added, “Christina brings a degree of openness and authenticity that resonates deeply with us at TG. We’re honored to collaborate with her as she shares her perspective and as we collectively look towards what’s subsequent in MS. At TG Therapeutics, we stay dedicated to advancing innovation and supporting efforts that maintain these dwelling with MS on the middle of all the things we do.”

TG’s concentrate on advancing innovation in a number of sclerosis contains not solely the event of novel therapies, but in addition a dedication to supporting sources that assist folks dwelling with MS really feel knowledgeable and empowered all through their care journey.

ABOUT WWW.NEXTINMS.COM
Subsequent In MS^TM is a platform designed to create area for folks dwelling with MS to have sincere conversations about their expertise and discover collectively what comes subsequent, on their very own phrases. The platform facilities on actual, unfiltered dialogue, together with conversations between Christina Applegate and others dwelling with MS, and displays the on a regular basis realities, questions, and selections that form life with the illness. Subsequent In MS is meant to assist folks dwelling with MS in carrying that openness past the platform, into conversations with relations, buddies, and healthcare professionals, when and the way they select. The platform is designed to evolve over time as these conversations proceed.

ABOUT TG THERAPEUTICS 
TG Therapeutics is a completely built-in, industrial stage, biopharmaceutical firm targeted on the acquisition, growth and commercialization of novel remedies for B-cell ailments. As well as to a analysis pipeline, TG Therapeutics has a product accepted by the U.S. Meals and Drug Administration (FDA) for the therapy of grownup sufferers with relapsing kinds of a number of sclerosis, together with clinically remoted syndrome, relapsing-remitting illness, and energetic secondary progressive illness, and by a number of regulatory companies exterior of the U.S to deal with grownup sufferers with RMS who’ve energetic illness outlined by scientific or imaging options. For extra info, go to www.tgtherapeutics.com, and comply with us on X @TGTherapeutics and on LinkedIn.

Cautionary Assertion
This press launch incorporates forward-looking statements that contain a quantity of dangers and uncertainties. All statements contained on this press launch apart from statements of historic information, together with statements concerning our collaboration with Christina Applegate, and the www.nextinms.com platform might represent forward-looking statements. For these statements, we declare the safety of the protected harbor for forward-looking statements contained within the Personal Securities Litigation Reform Act of 1995.

Any forward-looking statements on this press launch are primarily based on administration’s present expectations and beliefs and are topic to a quantity of dangers, uncertainties and essential elements that will trigger precise occasions or outcomes to differ materially from these expressed or implied by any forward-looking statements contained on this press launch.

Extra elements that would trigger our precise outcomes to differ materially embody the next: the Firm’s means to proceed to commercialize their marketed product; the chance that the collaboration with Christina Applegate, doesn’t go as deliberate; the chance that the www.nextinms.com platform doesn’t acquire traction or ceases to exist; the chance that due to regulatory enforcement or different causes any portion of the collaboration described right this moment shouldn’t be in a position to be carried out; the chance that the Firm doesn’t obtain its 2026 growth pipeline anticipated milestones or objectives within the timeframe projected or in any respect; the uncertainties usually inherent in analysis and growth; regulatory developments, legislative actions, govt orders, together with the imposition of tariffs and coverage adjustments within the U.S. and different jurisdictions; and common political, financial and enterprise situations. Additional dialogue about these and different dangers and uncertainties might be present in our Annual Report on Type 10-Ok for the fiscal yr ended December 31, 2024 and in our different filings with the Securities and Trade Fee.

Any forward-looking statements set forth on this press launch converse solely as of the date of this press launch. We don’t undertake to replace any of these forward-looking statements to mirror occasions or circumstances that happen after the date hereof. This press launch and prior releases can be found at www.tgtherapeutics.com. The knowledge discovered on our web site shouldn’t be included by reference into this press launch and is included for reference functions solely.

CONTACT:

Investor Relations
E mail:ir@tgtxinc.com
Phone: 1.877.575.TGTX (8489), Choice 4

Media Relations
E mail:media@tgtxinc.com
Phone: 1.877.575.TGTX (8489), Choice 6

^{1. MS Prevalence. Nationwide Multiple Sclerosis Society web site. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis Worldwide Federation, 2013 through Knowledge monitor p. 236.}